In this digital era, both kids and adults are often glued to smartphone screens. Digital technology keeps users entertained, ...

A large-scale study published in the Journal of Affective Disorders has found that adolescents who experienced more intense ...

A new meta-analysis suggests that people with major depressive disorder have lower levels of the brain antioxidant ...

By Mariam Sunny and Christy Santhosh (Reuters) -Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm ...

A McGill-led study could change the way this new treatment is administered in hospitals and clinics. A first-of-its-kind ...

Dark traits like narcissism and psychopathy are often associated with dysfunction, but new findings reveal that certain ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

A single dose of psilocybin coupled with “talk therapy” can significantly reduce depression in people with cancer for up to ...

A new study from the American Cancer Society’s medical journal found that psilocybin — the active ingredient in “magic ...

New research shows a single dose leads to 'robust' reductions in depression and anxiety up to 2 years afterward.

The psilocybin found in "magic mushrooms" might be key to quelling depression among people battling cancer, a new study found ...

A first-of-its-kind clinical trial shows that ketamine treatment for severe, treatment-resistant depression is significantly ...